Gilead Sciences Inc. (GILD)

Oncology Corporate Profile

Stock Performance

67.5000
0.0000

HQ Location

333 Lakeside Drive
Foster City, CA 94404

Company Description

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Website: http://www.gilead.com/

Brand Generic Indication
Zydelig?? IdelalisibZydelig is indicated in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. Accelerated approval was granted for FL and SLL based on overall response rate.



Zydelig is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells. -
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GS-1101 (CAL-101)PI3K inhibitor1st line metastatic Chronic Lymphocytic Leukemia (CLL)III
Idelalisibp13k delta inhibitorChronic Lymphocytic Leukemia (CLL)III
GS-5745MMP9 mAb inbitorGastric cancerIII
momelotinibJAK inhibitorMyelofibrosisIII
entospletinibSyk inhibitorAcute Myelogenous Leukemia (AML)II
GS-4059BTK inhibitorB-cell malignanciesII
GS-6624 monoclonal antibody (humanized)Colorectal cancerII
simtuzumabmonoclonal antibodyColorectal cancerII
simtuzumabmonoclonal antibodyMyelofibrosisII
CYT387JAK inhibitorMyelofibrosisII
simtuzumabmonoclonal antibodyPancreatic cancerII
GS-6624 monoclonal antibody (humanized)Pancreatic cancerII
momelotinibJAK inhibitorPancreatic cancerII
GS-9973syk inhibitorVarious cancer typesII
entospletinibSyk inhibitorVarious cancer typesII
GS-9901p13k delta inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.gilead.com/

Recent News Headlines

Gilead hepatitis C drug patent faces European challenge

3/27/2017 08:02 am

[Reuters] - Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir, sold by the U.S. drugmaker as Sovaldi, is transforming the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier. The campaigners argue that the patent on the drug is open to challenge because the science behind sofosbuvir is not new.

British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic hepatitis C infection

3/21/2017 08:00 pm

[CNW Group] - British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic hepatitis C infection

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ

3/20/2017 04:02 pm

[CNW Group] - EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ